Among the brightest antipsoriatic stars

Affiliations

Comment

K Meier et al. Br J Dermatol. 2020 Aug.

. 2020 Aug;183(2):201-202.

doi: 10.1111/bjd.18867. Epub 2020 Feb 3.

¹ Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.

No abstract available

Comment on

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Thaçi D, et al. Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20. Br J Dermatol. 2020. PMID: 31705526 Clinical Trial.

1. Ghoreschi K, Bruck J, Kellerer C et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208:2291-303.
1. Mrowietz U, Szepietowski JC, Loewe R et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE). Br J Dermatol 2017; 176:615-23.
1. Warren RB, Mrowietz U, von Kiedrowski R et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528-37.
1. Thaçi D, Pinter A, Sebastian M et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol 2020; 183:265-75.
1. Sticherling M, Mrowietz U, Augustin M et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol 2017; 177:1024-32.